Roche’s portfolio of cervical cancer screening products combines high sensitivity and high specificity to provide the most comprehensive strategy for cervical cancer prevention and treatment. Roche supports your efforts to provide the best patient care, from identifying patients who can forego triage to detecting patients who need immediate intervention.
cobas® HPV Test identifies all high-risk genotypes together with individual results for the most aggressive HPV genotypes (16 and 18).2
CINtec® PLUS Kit detects and stains for p16/Ki-67 biomarkers to triage those patients with less aggressive/other high-risk HPV genotypes and identify women with transforming lesions (p16/Ki-67 positive) who need colposcopy.3,4
1. Cox JT, Castle PE, Behrens CM, et al. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing and genotyping for HPV 16/18: results from ATHENA HPV study. Am J Ob Gyn. 2012:in Press.
2. cobas® 4800 HPV Test US package insert. April 2011.
3. Petry KU, Schmidt D, Scherbring S, et al. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 dual-stained cytology. Gynecol Oncol.2011;121(3):505-509.
4. Schmidt D, Bergeron C, Denton KJ, Ridder R, European CINtec Cytology Study Group. p16/Ki-67 dual-stain cytology in the triage of ASCUS and LSIL Papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol. 2011;119:158-166.
5. Bergeron C, Ordi J, Schmidt D, Trunk MJ, Keller T, Ridder R, European CINtec Histology Study Group. Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol. 2010;133(3):395-406.